Pharmaceutical

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

Next Article

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Cancer drug shortages have plagued the U.S. for years. Can they be fixed?

STAT+: Cancer drug shortages have plagued the U.S. for ...

Apr 5, 2023

QBiotics wins FDA orphan status for rainforest-derived cancer drug

QBiotics wins FDA orphan status for rainforest-derived ...

Feb 16, 2024

STAT+: Lawmakers eye partial increase for Medicare doctor pay

STAT+: Lawmakers eye partial increase for Medicare doct...

Feb 13, 2024